美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Ethinyl Estradiol/Levonorgestrel	Tablet			Develop a dissolution method			2024/01/03
Ethinyl Estradiol/Norethindrone	Tablet (Chewable)	II (Paddle)	75	0.09% Sodium Lauryl Sulfate in 0.1 N HCl	500	10, 15, 20, 30 and 45	2008/01/14
Ethinyl Estradiol/Norethindrone	Tablet			Refer to USP			2009/07/15
Ethinyl Estradiol/Norethindrone Acetate	Tablet			Refer to USP			2009/07/15
Ethinyl Estradiol/Norethindrone Acetate	Capsule	II (Paddle)	100	Phosphate Buffer, pH 6.8, containing 0.07% w/v Triton X 100	900	5, 10, 20, 30, 45, 60 and 75	2018/02/15
Ethinyl Estradiol/Norethindrone Acetate [0.01mg,0.01 mg;1 mg]	Tablet (Chewable)	II (Paddle)	75	0.025 M Na Acetate Buffer with 0.15% Sodium Lauryl Sulfate [SLS] (pH 5.0) [degassed]	500	10, 15, 20, 30 and 45	2015/12/24
Ethinyl Estradiol/Norethindrone Acetate [0.02mg;1mg]	Tablet (Chewable)	II (Paddle)	75	0.025 M Sodium Acetate Buffer with 0.15% SLS, pH 5.0	600	10, 15, 20, 30 and 45	2014/02/14
Ethinyl Estradiol/Norgestimate	Tablet			Develop a dissolution method			2023/09/15
Ethinyl Estradiol/Norgestimate (AB)	Tablet			Develop a dissolution method			2023/09/15
Ethinyl Estradiol/Norgestrel	Tablet			Develop a dissolution method			2023/09/15
Ethinyl Estradiol; Norelgestromin	Film, Transdermal	Modified USP Type V (Paddle-over-disk)	50	0.1% Hydroxypropyl-beta-cyclodextrin at 32º C	900	0.25, 0.5, 1, 2, 4, 8, 12, 16, 20 and 24 hours	2009/05/20
Ethionamide	Tablet	I (Basket)	75	0.1 N HCl	900	10, 20, 30, 45 and 60	2013/01/31
Ethosuximide	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Etidronate Disodium	Tablet			Develop a dissolution method			2024/01/03
Etodolac	Tablet			Refer to USP			2008/01/14
Etodolac	Tablet (Extended Release)			Refer to USP			2010/06/24
Etoposide	Capsule			Refer to USP			2010/06/24
Etrasimod Arginine	Tablet	II (Paddle)	75	50 mM Phosphate buffer w/0.2% Tween 20, pH 6.8	900	5, 15, 20, 30 and 45	2024/11/15
Etravirine (200 mg)	Tablet	II (Paddle)	70	1.0 % Sodium lauryl sulfate (SLS) in 0.01 M HCl in two phases: Phase 1: 1000 mL of degassed 0.01 M HCl for 10 minutes. Phase 2: Add 800 mL of 2.25% SLS in 0.01 M HCl.	1000 (phase 1): 1800 (phase 2)	Phase 1: No Sampling. Phase 2: 5, 10, 20, 30, 45, 60 and 90	2011/06/30
Etravirine (25 and 100 mg)	Tablet	II (Paddle)	50	1.0 % Sodium lauryl sulfate (SLS) in 0.01 M HCl in two phases: Phase 1: 500 mL of degassed 0.01 M HCl for 10 minutes. Phase 2: Add 400 mL of 2.25% SLS in 0.01 M HCl.	500 (phase 1): 900 (phase 2)	Phase 1: No Sampling. Phase 2: 5, 10, 20, 30, 45, 60 and 90	2014/08/14